PDL announces results of biological age reduction research

Ponce De Leon Health shares pilot results suggesting that its Rejuvant LifeTabs reduce biological age by an average of 8.5 years.

In the pilot, biological age was assessed by way of a DNA methylation biomarker; of the subjects in the analysis, two-thirds showed a statistically significant reduction in biological age.  The analysis was based on data from subjects who had taken PDL’s first commercial dietary supplement product: Rejuvant LifeTabs, for a period of four to six months.

Longevity.Technology: This news isn’t the paper coming out of Dr Kennedy’s lab at the Buck Institute, referred to by CEO and Founder, Tom Weldon during our Longevity 2020 event. That paper is expected show that they have statistically/ significantly increased healthspan and decreased morbidity. The timing of this announcement is probably a result of the company’s fundraising activity, but its outcomes are compelling nonetheless. 

The data were independently compiled by Dr. Yelena Budovskaya, Ph.D., co-founder and lead scientist of TruMe Labs, a pioneer in the emerging field of epigenetic aging testing.  Ponce de Leon is a distributor of TruMe’s TruAge Index, a take-at-home, non-invasive epigenetic age test.  The subjects included in the analysis represent all 17 customers who had taken a TruAge test at the time of their first purchase of Rejuvant, as well as a second test after taking the supplement for four to six months.  The TruAge Index measures DNA methylation, which is growing in acceptance by longevity researchers as an important biomarker of biological aging.

All formulations of LifeTabs are a GRAS cocktail of proprietary active ingredient LifeAKG™, which was shown in recent pre-clinical animal studies to increase lifespan (the length of life) and healthspan (the length of healthy life) in mammalian models. Ponce de Leon has eight patents pending for inventions arising from its research and development activities.

The Company’s CEO and Founder, Tom Weldon, commented “The pilot research data appears to be consistent with our earlier mammal results but we appreciate the need for a more robust study to validate this data on lifespan and healthspan research.  We look forward to conducting that study later this year and adding to these positive findings. The potential for Rejuvant to reverse epigenetic aging, as measured by DNA methylation testing and other measurable biological markers, may profoundly benefit not only the individuals who take the product, but also the economies and societies in which they participate and live.”

Ponce De Leon is currently enrolling participants for a larger, randomized, double-blind, placebo-controlled clinical trial, to be conducted at Indiana University Medical Center later this year. Back in early-May we were told by Tom Weldon that had been delayed by both Covid and the need close its $10 investment round.

The Company’s Chief Medical Officer, Francis R. Palmer, M.D., stated that “Although at this stage we only have consumer data, these findings are very promising.  We are only aware of one other published trial where researchers were able to show a reduction in biological age in humans as measured by DNA methylation.  In this other trial, modest reductions in biological age were observed in a small number of subjects who were treated with a combination of prescription drugs for a year.  The Rejuvant results are suggestive at this time but it showed a greater average reduction in biological age, achieved in six months, using non-prescription compounds.”  Added Palmer, “we expect our human clinical trial results to corroborate the encouraging data we have now, and we believe this will have a meaningful impact on both the scientific and consumer communities.”

Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Robotics and AI combine for new therapeutics discovery

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity. Two companies have joined forces in...

The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details. The global Longevity...